Health & Fitness
Tue, February 14, 2012
NEW YORK--([ BUSINESS WIRE ])--Pomerantz Haudek Grossman & Gross LLP is investigating claims on behalf of investors of SeraCare Life Sciences (aSeraCarea or the aCompanya) (NASDAQ: SRLS) (ISIN: US81747T1043) concerning the proposed acquisition of SeraCare by Linden Capital Partners (aLindena) in a cash transaction valued at approximately $82 million.
The investigation concerns whether the SeraCare directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, SeraCare shareholders would receive $4.00 in cash per share of SeraCare common stock. However, SeraCare has traded above $4.00 per share and at least one analyst has set a target price of $5.00 per share.
SeraCare shareholders seeking more information about this acquisition are advised to contact Gustavo Bruckner, Esq. at [ gfbruckner@pomlaw.com ] or 212-661-1100 or toll free at 888-476-6529, ext. 302. Shareholders may also contact Rebecca Jarmon at [ rjarmon@pomlaw.com ] or 212-661-1100 or 888-476-6529, ext. 314.
The Pomerantz Firm, with offices in New York, Chicago, and Washington, D.C., is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See [ www.pomerantzlaw.com ].
